Literature DB >> 29999236

Biodegradable, Drug-Loaded Nanovectors via Direct Hydration as a New Platform for Cancer Therapeutics.

Roxane Ridolfo1, Benjamin C Ede2, Paraskevi Diamanti2,3, Paul B White4, Adam W Perriman2, Jan C M van Hest1, Allison Blair2,3, David S Williams1,5.   

Abstract

The stabilization and transport of low-solubility drugs, by encapsulation in nanoscopic delivery vectors (nanovectors), is a key paradigm in nanomedicine. However, the problems of carrier toxicity, specificity, and producibility create a bottleneck in the development of new nanomedical technologies. Copolymeric nanoparticles are an excellent platform for nanovector engineering due to their structural versatility; however, conventional fabrication processes rely upon harmful chemicals that necessitate purification. In engineering a more robust (copolymeric) nanovector platform, it is necessary to reconsider the entire process from copolymer synthesis through self-assembly and functionalization. To this end, a process is developed whereby biodegradable copolymers of poly(ethylene glycol)-block-poly(trimethylene carbonate), synthesized via organocatalyzed ring-opening polymerization, undergo assembly into highly uniform, drug-loaded micelles without the use of harmful solvents or the need for purification. The direct hydration methodology, employing oligo(ethylene glycol) as a nontoxic dispersant, facilitates rapid preparation of pristine, drug-loaded nanovectors that require no further processing. This method is robust, fast, and scalable. Utilizing parthenolide, an exciting candidate for treatment of acute lymphoblastic leukemia (ALL), discrete nanovectors are generated that show strikingly low carrier toxicity and high levels of specific therapeutic efficacy against primary ALL cells (as compared to normal hematopoietic cells).
© 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  acute leukemia; drug delivery; nanomedicine; parthenolide; self-assembly

Mesh:

Substances:

Year:  2018        PMID: 29999236     DOI: 10.1002/smll.201703774

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  6 in total

1.  Intravitreal Polymeric Nanocarriers with Long Ocular Retention and Targeted Delivery to the Retina and Optic Nerve Head Region.

Authors:  Vijayabhaskarreddy Junnuthula; Amir Sadeghi Boroujeni; Shoupeng Cao; Shirin Tavakoli; Roxane Ridolfo; Elisa Toropainen; Marika Ruponen; Jan C M van Hest; Arto Urtti
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

2.  Mechanochemical preparation of triptolide-loaded self-micelle solid dispersion with enhanced oral bioavailability and improved anti-tumor activity.

Authors:  Dabu Zhu; Qiuqin Zhang; Yifang Chen; Minghua Xie; Jianbo Li; Shen Yao; Ming Li; Zhao Lou; Yue Cai; Xuanrong Sun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 3.  The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.

Authors:  Tao An; Huanhuan Yin; Yanting Lu; Feng Liu
Journal:  Drug Des Devel Ther       Date:  2022-04-29       Impact factor: 4.319

4.  A facile method for anti-cancer drug encapsulation into polymersomes with a core-satellite structure.

Authors:  Hongchao Xu; Weiwei Cui; Zhitao Zong; Yinqiu Tan; Congjun Xu; Jiahui Cao; Ting Lai; Qi Tang; Zhongjuan Wang; Xiaofeng Sui; Cuifeng Wang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

5.  Exploring the Impact of Morphology on the Properties of Biodegradable Nanoparticles and Their Diffusion in Complex Biological Medium.

Authors:  Roxane Ridolfo; Shirin Tavakoli; Vijayabhaskarreddy Junnuthula; David S Williams; Arto Urtti; Jan C M van Hest
Journal:  Biomacromolecules       Date:  2020-06-26       Impact factor: 6.988

6.  Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide.

Authors:  Benjamin C Ede; Rafal R Asmaro; John P Moppett; Paraskevi Diamanti; Allison Blair
Journal:  Haematologica       Date:  2018-05-17       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.